Literature DB >> 9554878

Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies.

P K Jadhav1, F J Woerner, P Y Lam, C N Hodge, C J Eyermann, H W Man, W F Daneker, L T Bacheler, M M Rayner, J L Meek, S Erickson-Viitanen, D A Jackson, J C Calabrese, M Schadt, C H Chang.   

Abstract

Comparison of the high-resolution X-ray structures of the native HIV-1 protease and its complexes with the inhibitors suggested that the enzyme flaps are flexible. The movement at the tip of the flaps could be as large as 7 A. On the basis of this observation, cyclic cyanoguanidines have been designed, synthesized, and evaluated as HIV-1 protease (PR) inhibitors. Cyclic cyanoguanidines were found to be very potent inhibitors of HIV-1 protease. The choice of cyclic cyanoguanidines over cyclic guanidines was based on the reduced basicity of the former. X-ray structure studies of the HIV PR complex with cyclic cyanoguanidine demonstrated that in analogy to cyclic urea, cyclic cyanoguanidines also displace the unique structural water molecule. The structure-activity relationship of the cyclic cyanoguanidines is compared with that of the corresponding cyclic urea analogues. The differences in binding constants of the two series of compounds have been rationalized using high-resolution X-ray structure information.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9554878     DOI: 10.1021/jm970524i

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

1.  Inhibition and substrate recognition--a computational approach applied to HIV protease.

Authors:  H M Vinkers; M R de Jonge; E D Daeyaert; J Heeres; L M H Koymans; J H van Lenthe; P J Lewi; H Timmerman; P A J Janssen
Journal:  J Comput Aided Mol Des       Date:  2003-09       Impact factor: 3.686

2.  Quantitative structure-activity relationship by CoMFA for cyclic urea and nonpeptide-cyclic cyanoguanidine derivatives on wild type and mutant HIV-1 protease.

Authors:  Speranta Avram; Cristian Bologa; Maria-Luiza Flonta
Journal:  J Mol Model       Date:  2005-02-16       Impact factor: 1.810

3.  Multiple receptor conformation docking and dock pose clustering as tool for CoMFA and CoMSIA analysis - a case study on HIV-1 protease inhibitors.

Authors:  Sree Kanth Sivan; Vijjulatha Manga
Journal:  J Mol Model       Date:  2011-05-06       Impact factor: 1.810

4.  Can cyclic HIV protease inhibitors bind in a non-preferred form? An ab initio, DFT and MM-PB(GB)SA study.

Authors:  Daniel P Oehme; Robert T C Brownlee; David J D Wilson
Journal:  J Mol Model       Date:  2012-11-13       Impact factor: 1.810

5.  Identification of novel HIV 1--protease inhibitors: application of ligand and structure based pharmacophore mapping and virtual screening.

Authors:  Divya Yadav; Sarvesh Paliwal; Rakesh Yadav; Mahima Pal; Anubhuti Pandey
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.